Business
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase
About this update from Dyne Therapeutics, Inc.
[{"type":"text","content":"- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD - - Oral presentation on Phase 3 trial design for z-basivarsen in DM1 - - Five total presentations across three neuromuscular diseases demonstrate strength of Dyne’s pipeline based on clinically-validated FORCE™ platform - WALTHAM, Mass., Feb. 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that five presentations, including three oral presentations, highlighting the company’s Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease programs will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 8-11, 2026, in Orlando, FL, and virtually. “Late last year, we presented positive topline results for the DELIVER trial in DMD demonstrating unprecedented breadth and durability of functional improvement across upper limb, lower limb, trunk and pulmonary muscle groups. We are excited to build on those results with the presentation of new long-term data showing potential preservation of cardiopulmonary function,” said John Cox, president and chief executive officer of Dyne. “These clinical data provide further validation of our FORCE™ platform and its potential to be best-in-class in delivering a therapeutic payload across relevant tissues to drive functional improvement for patients with neuromuscular diseases. This same platform is being used across our other pipeline programs, and we are excited to also be presenting the design of a robust Phase 3 trial of z-basivarsen in DM1, which we believe will be field defining, as well as additional preclinical data for our program in Pompe disease.” Dyne’s posters and presentations at the 2026 MDA Clinical & Scientific Conference will include: New analyses of the results of the DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in exon 51 skip amenable DMD.The design of a Phase 3 clinical trial assessing zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in DM1.New preclinical data for DYNE-401, Dyne’s product candidate being developed for individuals living with Pom...